Detection of exon 12 type A mutation of NPM1 gene in IMS-M2 cell line

被引：11

作者：

Chi, Hoang Thanh ^{[1
,2
]}

Vu, Hoang Anh ^{[1
]}

Iwasaki, Reo ^{[1
,2
]}

Nagamura, Fumitaka ^{[3
]}

Tojo, Arinobu ^{[3
]}

Watanabe, Toshiki ^{[2
]}

Sato, Yuko ^{[1
]}

机构：

[1] Int Med Ctr Japan, Res Inst, Dept Pathol, Div Ultrafine Struct,Shinjuku Ku, Tokyo 1628655, Japan

[2] Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Tokyo, Japan

[3] Univ Tokyo, Inst Med Sci, Res Hosp, Dept Hematol Oncol,Div Mol Therapy, Tokyo, Japan

来源：

LEUKEMIA RESEARCH | 2010年 / 34卷 / 02期

关键词：

NPM1; AML; ACUTE MYELOGENOUS LEUKEMIA; NUCLEOPHOSMIN; P53; EXPRESSION; ARF;

D O I：

10.1016/j.leukres.2009.09.019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Nucleophosmin 1 (NPM1), a protein that shuttles between the nucleus and cytoplasm, is mostly located in nucleoli. This is a multifunctional phosphoprotein to which both tumor-suppressor and oncogenic functions have been attributed. Here, we have found the cell line with the type A NPM1 mutation and with the other genetic alterations including ETV6-NTRC fusion. It will provide a good in vitro model for bio-molecular studies of interaction of mutated NPM1 gene and other genetic abnormalities as well as a useful tool for developing new molecularly targeted drugs. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：261 / 262

页数：2

共 15 条

[1]

Bernard K, 2003, CANCER RES, V63, P6716

[2]

Nucleophosmin regulates the stability and transcriptional activity of p53 [J].

Colombo, E ;

Marine, JC ;

Danovi, D ;

Falini, B ;

Pelicci, PG .

NATURE CELL BIOLOGY, 2002, 4 (07) :529-533

[3]

Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25) [J].

Eguchi, M ;

Eguchi-Ishimae, M ;

Tojo, A ;

Morishita, K ;

Suzuki, K ;

Sato, Y ;

Kudoh, S ;

Tanaka, K ;

Setoyama, M ;

Nagamura, F ;

Asano, S ;

Kamada, N .

BLOOD, 1999, 93 (04) :1355-1363

[4]

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. [J].

Falini, B ;

Mecucci, C ;

Tiacci, E ;

Alcalay, M ;

Rosati, R ;

Pasqualucci, L ;

La Starza, R ;

Diverio, D ;

Colombo, E ;

Santucci, A ;

Bigerna, B ;

Pacini, R ;

Pucciarini, A ;

Liso, A ;

Vignetti, M ;

Fazi, P ;

Meani, N ;

Pettirossi, V ;

Saglio, G ;

Mandelli, F ;

Lo-Coco, F ;

Pelicci, P ;

Martelli, MF .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (03) :254-266

[5]

The ARF tumour suppressor [J].

Gallagher, Stuart J. ;

Kefford, Richard F. ;

Rizos, Helen .

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2006, 38 (10) :1637-1641

[6]

Gilliland D Gary, 2004, Hematology Am Soc Hematol Educ Program, P80

[7]

The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial [J].

Grimwade, D ;

Walker, H ;

Oliver, F ;

Wheatley, K ;

Harrison, C ;

Harrison, G ;

Rees, J ;

Hann, I ;

Stevens, R ;

Burnett, A ;

Goldstone, A .

BLOOD, 1998, 92 (07) :2322-2333

[8]

Characterisation of the interface between nucleophosmin (NPM) and p53: Potential role in p53 stabilisation [J].

Lambert, B ;

Buckle, M .

FEBS LETTERS, 2006, 580 (01) :345-350

[9]

Nozawa Y, 1996, J PATHOL, V178, P48

[10]

Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin [J].

Quentmeier, H ;

Martelli, MP ;

Dirks, WG ;

Bolli, N ;

Liso, A ;

Macleod, RAF ;

Nicoletti, I ;

Mannucci, R ;

Pucciarini, A ;

Bigerna, B ;

Martelli, M ;

Mecucci, C ;

Drexler, HG ;

Falini, B .

LEUKEMIA, 2005, 19 (10) :1760-1767

← 1 2 →